Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI

This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.

Inclusion Criteria:

• patients undergoing revascularization for significant coronary artery disease
• age range 21-85 years

Exclusion Criteria:

• non-STEMI, STEMI
• cancer
• renal failure with creatinine>3.0mg/dl
• liver cirrhosis
• lymphoproliferative disorder
• pregnancy
• thrombocytopenia<150'000
• coagulopathy (INR>1.5)
• abnormal liver function tests
• illicit drug use
• history of statin intolerance
• history of rhabdomyolysis
• planned use of Glycoprotein IIb/IIIa inhibitors during PCI
• current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin